News | Radiopharmaceuticals and Tracers | May 13, 2016

Blue Earth Diagnostics Opens U.S. Office, Expands Management Team

Massachusetts office will provide support for development and commercialization of PET imaging agent pending FDA approval

Blue Earth Diagnostics, U.S. headquarters, management expansion, PET imaging agent

May 13, 2016 — Blue Earth Diagnostics, a molecular imaging diagnostics company, announced it has established operations in the United States in Burlington, Mass. The company develops and commercializes innovative positron emission tomography (PET) imaging products that address unmet needs in cancer.

The Massachusetts headquarters will provide sales, marketing and medical affairs support for the development and commercialization of fluciclovine F-18, the company’s PET imaging agent currently under Priority Review with the U.S. Food and Drug Administration (FDA).

The company also announced the creation of key appointments for Blue Earth Diagnostics Inc.:  Michael W. Heslop, as president; Peter Gardiner, MB ChB, MRCP, FFPM, as vice president, medical affairs; Bradley K. Pounds as vice president, sales, U.S.; David Pendleton, vice president, marketing; Christa Dhimo, vice president, strategy & execution, U.S.; and Priscilla Harlan, vice president, corporate communications.

Blue Earth Diagnostics Inc. is a wholly-owned subsidiary of U.K.-based Blue Earth Diagnostics Ltd.

For more information: www.blueearthdiagnostics.com

Related Content

NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
Houston Methodist Hospital Acquires Focal One High-Intensity Focused Ultrasound System
News | Focused Ultrasound Therapy | March 19, 2019
EDAP TMS SA announced that Houston Methodist Hospital, one of the first hospitals in the U.S. to offer Ablatherm...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case
News | Treatment Planning | March 08, 2019
Anderson Regional Cancer Center in Meridian, Miss., has treated its first patient using the combination of RaySearch's...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...